New tools unveiled at AAIC 2025 aim to detect Alzheimer’s earlier and faster, even in low-resource settings
Key Highlights:
• AI model trained on 100+ datasets predicts Alzheimer’s risk early, targeting over 400M people globally
• Cognitive scores estimated without scans or lab tests using basic patient data
• AI-powered pipeline speeds up discovery of drugs targeting Alzheimer’s proteins
IGC Pharma (NYSE American: IGC) announced three new AI-driven tools for Alzheimer’s research at the Alzheimer’s Association International Conference (AAIC) 2025. The company introduced MINT-AD, an AI model trained on over 100 diverse datasets to predict Alzheimer’s risk and cognitive decline using clinical, lifestyle, and demographic data. It’s designed for use in everyday clinics, especially in underserved regions.
IGC also showcased a new approach using large language models to predict cognitive test scores (MMSE and CSI-D) using only socioeconomic data—eliminating the need for brain scans or blood tests. This could make early detection accessible in areas with limited healthcare infrastructure. Additionally, IGC revealed its AI-powered drug discovery pipeline focused on GLP-1 and CB1 targets, which helps rapidly identify promising Alzheimer’s drug candidates and speeds up lab validation. These developments position IGC Pharma as a key innovator in using AI for early diagnosis and faster treatment development in Alzheimer’s care.
About IGC Pharma
IGC Pharma (NYSE American: IGC) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for Alzheimer’s disease and related disorders. By combining traditional drug development with advanced artificial intelligence, IGC Pharma is accelerating early diagnosis, improving patient targeting, and streamlining drug discovery. Its lead candidate, IGC-AD1, is currently in Phase 2 trials, alongside a growing pipeline targeting neurodegeneration, tau proteins, and metabolic dysfunctions. The company is committed to transforming Alzheimer’s care through data-driven, accessible, and effective solutions.
By
